Saxenda does come with a high list price, yet that number is mostly a reference point rather than the amount most people actually pay out of pocket
It offers robust glucose lowering and has shown up to 15% weight reduction in certain populations
Blending can damage the liposomes
Potential areas of expansion include: Cardiovascular outcomes: A dedicated CVOT, if not already required as a post-marketing commitment, would evaluate whether orforglipron reduces MACE in patients with established cardiovascular disease or high cardiovascular risk, following the precedent set by the SELECT trial for semaglutide
At $199 per month (or as low as $99 during flash sales), BlueWater offers exceptional value without compromising quality or medical supervision
Retatrutide is expected to launch with weight loss data that beats tirzepatide by 4 to 6 percentage points, which justifies premium pricing in Lillys framework